ABIVAX Société Anonyme
ABVXHealthcareNASDAQBiotechnology · Last scanned Sep 9, 2026
Scan Results
Daily timeframeABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic. At a $10.38B market cap, ABIVAX Société Anonyme ranks as a large-cap company within healthcare. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease.
Market Cap
$10.38B
Beta
-0.25
P/E (TTM)
—
P/E (Fwd)
-37.81
EPS (TTM)
$-5.35
EPS (Fwd)
$-3.15
ROE
-157.1%
ROA
-44.6%
Cash
$491.6M
Total Debt
$34.2M
Free CF
-$114.5M
52W Change
31.0%
Annual Financials
Cash vs Debt
Where ABVX stands vs its 150-day and 200-day moving averages
As of the September 2, 2026 close, ABVX finished 4.07% below its 150-day moving average ($118.49) and 4.74% below its 200-day moving average ($119.33). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ABVX overbought or oversold?
At the September 2, 2026 close, ABVX's RSI(14) was 29.2, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
ABIVAX Société Anonyme holds $491.6M in cash against $34.2M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$114.5M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -157.1%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
ABVX's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing ABVX's risk profile alongside its fundamentals and technical indicators provides a more complete picture.